BIOCURE TECHNOLOGY INC. (F:1WH) — Market Cap & Net Worth
Market Cap & Net Worth: BIOCURE TECHNOLOGY INC. (1WH)
BIOCURE TECHNOLOGY INC. (F:1WH) has a market capitalization of $960.84K (€821.86K) as of July 22, 2026. Listed on the F stock exchange, this Germany-based company holds position #30610 globally and #2689 in its home market, demonstrating a 34.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOCURE TECHNOLOGY INC.'s stock price €0.03 by its total outstanding shares 94000496 (94.00 Million). Review BIOCURE TECHNOLOGY INC. (1WH) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
BIOCURE TECHNOLOGY INC. Market Cap History: 2021 to 2026
BIOCURE TECHNOLOGY INC.'s market capitalization history from 2021 to 2026. Data shows change from $67.26 Million to $2.80 Million (-53.39% CAGR).
BIOCURE TECHNOLOGY INC. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOCURE TECHNOLOGY INC.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 1WH by Market Capitalization
Companies near BIOCURE TECHNOLOGY INC. in the global market cap rankings as of July 22, 2026.
Key companies related to BIOCURE TECHNOLOGY INC. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #560 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $480.50 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $672.15 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €753.60 |
| #560 | UCB SA | BR:UCB | $47.34 Billion | €238.00 |
BIOCURE TECHNOLOGY INC. Historical Marketcap From 2021 to 2026
Between 2021 and today, BIOCURE TECHNOLOGY INC.'s market cap moved from $67.26 Million to $ 2.80 Million, with a yearly change of -53.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.80 Million | +112.50% |
| 2025 | €1.32 Million | -41.75% |
| 2024 | €2.26 Million | +357.78% |
| 2023 | €494.53K | 0.00% |
| 2022 | €494.53K | -99.26% |
| 2021 | €67.26 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of BIOCURE TECHNOLOGY INC. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $960.84K USD |
| MoneyControl | $960.84K USD |
| MarketWatch | $960.84K USD |
| marketcap.company | $960.84K USD |
| Reuters | $960.84K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BIOCURE TECHNOLOGY INC.
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T … Read more